T M Laursen1, P B Mortensen1, J H MacCabe2, D Cohen3, C Gasse1. 1. National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark. 2. Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, London, UK. 3. Department of Severe Mental Illness, Mental Health Organization North-Holland North, The Netherlands.
Abstract
BACKGROUND: Cardiovascular (CV) co-morbidity is one of the major modifiable risk factors driving the excess mortality in individuals with schizophrenia or bipolar disorder. Population-based studies in this area are sparse. METHOD: We used Danish population registers to calculate incidence rate ratios (IRRs) for CV drug use, and mortality rate ratios comparing subjects with schizophrenia or bipolar disorder with subjects with no prior psychiatric hospitalization. RESULTS: IRRs for CV prescriptions were significantly decreased in patients with schizophrenia or bipolar disorder compared with the general population. Among persons without previous myocardial infarction (MI) or cerebrovascular disease, persons with schizophrenia or bipolar disorder had an up to 6- and 15-fold increased mortality from all causes or unnatural causes, respectively, compared with the general population, being most pronounced among those without CV treatment (16-fold increase). Among those with previous MI or cerebrovascular disease, excess all-cause and unnatural death was lower (up to 3-fold and 7-fold increased, respectively), but was similar in CV-treated and -untreated persons. CONCLUSIONS: The present study shows an apparent under-prescription of most CV drugs among patients with schizophrenia or bipolar disorder compared with the general population in Denmark. The excess of mortality by unnatural deaths in the untreated group suggests that the association between CV treatment and mortality may be confounded by severity of illness. However, our results also suggest that treatment of CV risk factors is neglected in these patients.
BACKGROUND: Cardiovascular (CV) co-morbidity is one of the major modifiable risk factors driving the excess mortality in individuals with schizophrenia or bipolar disorder. Population-based studies in this area are sparse. METHOD: We used Danish population registers to calculate incidence rate ratios (IRRs) for CV drug use, and mortality rate ratios comparing subjects with schizophrenia or bipolar disorder with subjects with no prior psychiatric hospitalization. RESULTS: IRRs for CV prescriptions were significantly decreased in patients with schizophrenia or bipolar disorder compared with the general population. Among persons without previous myocardial infarction (MI) or cerebrovascular disease, persons with schizophrenia or bipolar disorder had an up to 6- and 15-fold increased mortality from all causes or unnatural causes, respectively, compared with the general population, being most pronounced among those without CV treatment (16-fold increase). Among those with previous MI or cerebrovascular disease, excess all-cause and unnatural death was lower (up to 3-fold and 7-fold increased, respectively), but was similar in CV-treated and -untreated persons. CONCLUSIONS: The present study shows an apparent under-prescription of most CV drugs among patients with schizophrenia or bipolar disorder compared with the general population in Denmark. The excess of mortality by unnatural deaths in the untreated group suggests that the association between CV treatment and mortality may be confounded by severity of illness. However, our results also suggest that treatment of CV risk factors is neglected in these patients.
Authors: Suraj Sarvode Mothi; Neeraj Tandon; Jaya Padmanabhan; Ian T Mathew; Brett Clementz; Carol Tamminga; Godfrey Pearlson; John Sweeney; Matcheri S Keshavan Journal: Schizophr Res Date: 2015-04-19 Impact factor: 4.939
Authors: Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2017-06 Impact factor: 49.548
Authors: Nancy H Liu; Gail L Daumit; Tarun Dua; Ralph Aquila; Fiona Charlson; Pim Cuijpers; Benjamin Druss; Kenn Dudek; Melvyn Freeman; Chiyo Fujii; Wolfgang Gaebel; Ulrich Hegerl; Itzhak Levav; Thomas Munk Laursen; Hong Ma; Mario Maj; Maria Elena Medina-Mora; Merete Nordentoft; Dorairaj Prabhakaran; Karen Pratt; Martin Prince; Thara Rangaswamy; David Shiers; Ezra Susser; Graham Thornicroft; Kristian Wahlbeck; Abe Fekadu Wassie; Harvey Whiteford; Shekhar Saxena Journal: World Psychiatry Date: 2017-02 Impact factor: 49.548
Authors: Helene Speyer; Hans Christian Brix Nørgaard; Carsten Hjorthøj; Thomas Axel Madsen; Søren Drivsholm; Charlotta Pisinger; Christian Gluud; Ole Mors; Jesper Krogh; Merete Nordentoft Journal: BMC Psychiatry Date: 2015-05-23 Impact factor: 3.630
Authors: Charlotte Woodhead; Mark Ashworth; Matthew Broadbent; Felicity Callard; Matthew Hotopf; Peter Schofield; Murat Soncul; Robert J Stewart; Max J Henderson Journal: Br J Gen Pract Date: 2016-04-25 Impact factor: 5.386